CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

BioConcept Ltd. has been recognized by Life Sciences Review Magazine as the exclusive recipient of “Top 10 Cell Culture Solutions Companies in Europe – 2023,” based on our proprietary methodology, reflecting its position in the industry. This profile has been developed by the Life Sciences Review research and editorial team based on insights from an interview with , .

BioConcept Ltd.
Making Recombination Protein Production Seamless

BioConcept Ltd.

Martin Howald, CEO and President, BioConcept Ltd.Martin Howald, CEO and President
Since its inception in 1992, BioConcept Ltd. has evolved from a producer of cell culture media for the research market into a recognized service provider for the pharmaceutical and biotechnology market. BioConcept Ltd. meets the high requirements in the areas of manufacturing, cleaning, quality control, and documentation and offers a high degree of flexibility in terms of customer formulations and customized packaging.

“We believe that only high-quality products lead to longterm market success and generate customer satisfaction and reputation,” says Martin Howald, CEO and president of BioConcept Ltd.

BioConcept Ltd. has, over the years, expanded its specialty and high-quality product range. The company is able to produce media, powders, and buffers according to customer requirements.

In addition, together with its cell line development partners, it has developed the proprietary media for the production of recombinant proteins and antibodies for use in therapeutic programs.

“Our nimble company architecture, specialized employees, and extensive experience allow us to address customer requests rather quickly and readily,” says Howald.

As BioConcept Ltd. interacts closely with its customers and listens to their needs and requirements, it receives valuable feedback from customers that helps improve products and services. Through regular customer audits, the company optimizes its processes and the quality of its products and services.

We continue to work intensively on the expansion of our distributor and customer network and are eager to establish strategic partnerships to bring our products and services to a larger and broader customer base

During the pandemic period, BioConcept Ltd. was quick to respond to the need for Covid vaccine manufacturing initiative and provide large quantities of buffers. Additionally, it also continued the production of CHO production media and biosimilars at the same time. This was accomplished without any impact or delay to its pharma customers, who rely on these products for various cancer therapies globally.

Even in the post-pandemic world, BioConcept Ltd. has managed to continue to guarantee high quality and short delivery times for its products and services. The company has been able to meet production dates and deadlines, and its flexibility has ensured that customers meet their own commitments and delivery dates.

“We continue to work intensively on the expansion of our distributor and customer network and are eager to establish strategic partnerships to bring our products and services to a larger and broader customer base,” says Howald.

Top 10 Cell Culture Solutions Companies in Europe – 2023
Current Issue

Company : BioConcept Ltd.

Management
Martin Howald, CEO and President

Thank you for Subscribing to Life Science Review Weekly Brief

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/bioconcept-ltd